Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Bntx | Mind Blowing Facts

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

MarketBeat

BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides

BioNTech shares sank yesterday as disappointing Q1 results prompted layoffs. But long-term investors still have ample reasons to load up on BNTX stock today.

Barchart

Nasdaq Rises Amid Middle East Uncertainty: Stock Market Today

Governments and global organizations are responding to the threat of a potential energy crisis stemming from the war in the Middle East.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here?

BioNTech shares are crashing as the company posted a disappointing Q4 release and announced cofounders departure by the end of 2026. Here’s why BNTX stock is still worth buying today.

Barchart

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

Benzinga

Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?

Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?

Barchart

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BioNTech SE (NASDAQ:BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earnings of 75 cents per share.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Benzinga

Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults.

Benzinga

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co (NYSE:BMY) shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).

Benzinga

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data

On Friday, BioNTech SE (NASDAQ:BNTX) and its partner Duality Biologics (Suzhou) Co., Ltd. released topline data from a Phase 3 trial in China evaluating trastuzumab pamirtecan (BNT323/DB-1303) versus trastuzumab emtansine (T-DM1) for HER2-positive unresectable or metastatic breast cancer patients who have previously received trastuzumab and a taxane-based chemotherapy.

Benzinga

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'

The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr.

Benzinga

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech SE (NASDAQ:BNTX) reported a narrower loss for the second quarter on Monday.

Benzinga

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech SE (NASDAQ:BNTX) reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

StockNews.com

3 Specialty Healthcare Providers Addressing Niche Markets

The healthcare industry is poised for growth driven by the rapid adoption of new and advanced medical technologies to enhance diagnosis. Hence, investors might consider investing in healthcare stocks, such as Agilent Technologies (A), BioNTech (BNTX), and STERIS (STE), which address niche markets. Read more….

StockNews.com

3 Biotech Stocks Revolutionizing Healthcare

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

StockNews.com

3 Genomic Stocks Unlocking the Secrets of DNA

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given this backdrop, investing in fundamentally sound genomics stocks like Illumina (ILMN), BioNTech (BNTX), and Bio-Techne Corp. (TECH) could be beneficial. Read more….

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Biotech Stocks to Watch in March for Success

The biotech industry is set for strong growth amid the growing need for personalized treatments, the rising number of chronic diseases, increased investment in research, and the use of advanced technologies. Therefore, investors could consider adding fundamentally strong biotech stocks Acorda Therapeutics (ACOR), BioNTech (BNTX), and Jazz Pharmaceuticals (JAZZ) to…

StockNews.com

3 Biotech Stock Sensations to Snatch up This Week

The future of the biotech industry appears promising, fueled by technology-driven advancements, increasing merger and acquisition maneuvers, and developing product pipelines. Given this backdrop, quality biotech stocks BioNTech SE (BNTX), Entrada Therapeutics (TRDA), and Incyte Corporation (INCY) could be wise to snatch up this week. Read on….

StockNews.com

Buy, Hold, or Sell? Analyzing 3 Biotech Stocks Investors Are Watching

Amid the use of advanced technologies, personalized medicines, demand for quality treatments and therapies, and an aging population, the biotech industry appears to be on a steady path for expansion. Given this backdrop, let’s analyze the fundamentals of Biogen (BIIB), BioNTech (BNTX), and Kura (KURA) to determine which of these…

StockNews.com

3 Biotech Stocks Offering Great Potential for Gains in October

The biotechnology sector has grown exceptionally, primarily driven by innovations that consistently establish the industry as a leading force in vital spheres such as healthcare, agriculture, and environmental equilibrium. Given the industry’s solid prospects, quality biotech stocks BioNTech (BNTX), Puma Biotechnology (PBYI), and Protalix BioTherapeutics (PLX) could be wise portfolio…

StockNews.com

Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Should You Be Investing In?

Amidst the biotech industry’s rapid growth and notable advancements, let’s analyze which of the two major players, Moderna (MRNA) and BioNTech (BNTX), is a more favorable investment choice in the current uncertain economic climate. Keep reading to find out.

StockNews.com

3 Buy Worthy Biotech Stocks for May

The biotech industry is well-positioned to witness significant growth with government support and breakthrough developments. Therefore, biotech stocks BioNTech SE (BNTX), Acorda Therapeutics (ACOR), and Shionogi (SGIOY) might be solid buys. Read on.

StockNews.com

4 Biotech Stocks to Keep an Eye on in 2023

The U.S. 2022 fourth-quarter GDP growth surpassed estimates and induced fresh optimism. On the other hand, the biotech industry is expected to witness robust demand despite macro uncertainties. So, given the stable prospects of the biotech sector, quality stocks Amgen (AMGN), BioNTech (BNTX), Exelixis (EXEL), and Taisho Pharmaceutical (TAIPY) could…

1 2 3

People

Dipanjan BanchurSince

722 stories

Steve Reitmeister

508 stories

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Health and Human Services

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.